X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9023) 9023
Newsletter (336) 336
Dissertation (41) 41
Magazine Article (40) 40
Newspaper Article (37) 37
Book Chapter (19) 19
Government Document (12) 12
Publication (9) 9
Book Review (7) 7
Conference Proceeding (4) 4
Paper (4) 4
Book / eBook (2) 2
Web Resource (2) 2
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
celecoxib (8686) 8686
humans (4687) 4687
male (2589) 2589
female (2272) 2272
animals (2217) 2217
sulfonamides - pharmacology (1530) 1530
pharmacology & pharmacy (1523) 1523
cox-2 inhibitors (1488) 1488
nonsteroidal antiinflammatory drugs (1459) 1459
middle aged (1387) 1387
oncology (1364) 1364
sulfonamides - therapeutic use (1337) 1337
cyclooxygenase-2 (1270) 1270
pyrazoles - pharmacology (1190) 1190
aged (1173) 1173
adult (1101) 1101
angiogenesis inhibitors (1076) 1076
cancer (1059) 1059
pyrazoles (1054) 1054
expression (1000) 1000
apoptosis (970) 970
rats (956) 956
mice (948) 948
anti-inflammatory agents, non-steroidal - adverse effects (921) 921
pyrazoles - therapeutic use (893) 893
anti-inflammatory agents, non-steroidal - therapeutic use (887) 887
sulfonamides - adverse effects (876) 876
rofecoxib (872) 872
cyclooxygenase 2 inhibitors - pharmacology (858) 858
osteoarthritis (853) 853
cyclooxygenase 2 (851) 851
cox-2 (833) 833
nonsteroidal anti-inflammatory drugs (795) 795
inflammation (787) 787
research (770) 770
cyclooxygenase inhibitors - pharmacology (762) 762
cyclooxygenase inhibitors - therapeutic use (761) 761
cyclooxygenase 2 - metabolism (740) 740
sulfonamides - administration & dosage (739) 739
rheumatoid-arthritis (729) 729
cyclooxygenase 2 inhibitors (709) 709
treatment outcome (688) 688
cyclooxygenase 2 inhibitors - therapeutic use (685) 685
analysis (664) 664
cell line, tumor (649) 649
risk (631) 631
membrane proteins (608) 608
care and treatment (606) 606
pyrazoles - administration & dosage (585) 585
cyclooxygenase inhibitors - adverse effects (583) 583
prevention (580) 580
dose-response relationship, drug (554) 554
cyclooxygenase-2 inhibitor (533) 533
medicine, general & internal (516) 516
apoptosis - drug effects (509) 509
risk factors (509) 509
drug therapy (507) 507
double-blind (503) 503
anti-inflammatory agents, non-steroidal - pharmacology (502) 502
pyrazoles - adverse effects (480) 480
drugs (477) 477
double-blind method (461) 461
aspirin (446) 446
pain (443) 443
inhibition (440) 440
gastrointestinal toxicity (434) 434
aged, 80 and over (428) 428
isoenzymes - antagonists & inhibitors (427) 427
biochemistry & molecular biology (412) 412
nsaids (410) 410
cell proliferation - drug effects (403) 403
cyclooxygenase 2 inhibitors - adverse effects (402) 402
chemoprevention (395) 395
cyclooxygenase 2 inhibitors - administration & dosage (394) 394
arthritis (392) 392
naproxen (386) 386
rheumatology (376) 376
disease models, animal (374) 374
chemistry, medicinal (370) 370
growth (367) 367
in-vitro (366) 366
medicine & public health (356) 356
medicine, research & experimental (356) 356
rats, sprague-dawley (353) 353
gastroenterology & hepatology (349) 349
time factors (347) 347
chemotherapy (345) 345
health aspects (345) 345
inhibitors (344) 344
surgery (335) 335
cyclooxygenase (334) 334
anti-inflammatory agents, non-steroidal - administration & dosage (330) 330
sulfones (328) 328
clinical trials (326) 326
drug therapy, combination (324) 324
cell biology (323) 323
ibuprofen (318) 318
angiogenesis (310) 310
osteoarthritis - drug therapy (310) 310
rats, wistar (310) 310
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9026) 9026
Chinese (136) 136
German (98) 98
French (87) 87
Spanish (71) 71
Japanese (52) 52
Russian (37) 37
Korean (33) 33
Portuguese (27) 27
Italian (16) 16
Persian (7) 7
Croatian (6) 6
Czech (5) 5
Danish (5) 5
Polish (5) 5
Norwegian (4) 4
Turkish (4) 4
Dutch (3) 3
Slovak (3) 3
Swedish (3) 3
Hungarian (2) 2
Arabic (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2375 - 2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require... 
Internal Medicine | RHEUMATOID-ARTHRITIS | CYCLO-OXYGENASE-2 | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY | DICLOFENAC | PREVENTION | RISK | OSTEOARTHRITIS | Celecoxib - administration & dosage | Recurrence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Secondary Prevention - methods | Aspirin - administration & dosage | Cyclooxygenase 2 Inhibitors - adverse effects | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Naproxen - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Aged, 80 and over | Aspirin - therapeutic use | Drug Therapy, Combination | Celecoxib - adverse effects | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Peptic Ulcer Hemorrhage - chemically induced | Celecoxib - therapeutic use | Proton Pump Inhibitors - therapeutic use | Naproxen - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Aged | Care and treatment | Aspirin | Anti-inflammatory drugs | Gastrointestinal diseases | Naproxen | Clinical trials | Arthritis | Complications and side effects | Medical research | Gastrointestinal bleeding | Medicine, Experimental | Drugs | Funding | Risk | Population studies | Hemorrhage | Evidence-based medicine | Bleeding | Incidence | Motivation | Safety | Nonsteroidal anti-inflammatory drugs | Digestive system | Risk reduction | Inflammation | Celecoxib | Patients | Anti-inflammatory agents | Diseases | Omeprazole | Random numbers | Inhibitors | Ulcers | Healing | Fatalities | Cyclooxygenase-2 | Cardiovascular diseases | Health risk assessment | Protons | Randomization | Analgesics | Endoscopy | Drug dosages | Mortality | Health risks | Hospitals
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals
Journal Article
Angewandte Chemie (International ed.), ISSN 1433-7851, 2017, Volume 56, Issue 38, pp. 11520 - 11524
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 2019, Volume 24, Issue 20, p. 3801
Glioblastoma multiforme (GBM) is the most malignant type of central nervous system tumor that is resistant to all currently used forms of therapy. Thus, more... 
MIGRATION | APOPTOSIS | COX-2 inhibitor-celecoxib | CYCLOOXYGENASE-2 | glioblastoma and immortalized keratinocytes | DRUG-DELIVERY | BIOCHEMISTRY & MOLECULAR BIOLOGY | HACAT | PROLIFERATION | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | biotinylated PAMAM G3 dendrimer | INVASION | human fibroblast | GROWTH | ACTIVATED-RECEPTOR-GAMMA | PPAR gamma agonist-Fmoc-L-Leucine | Necrosis - drug therapy | Leucine - pharmacology | Dendrimers - metabolism | Apoptosis - drug effects | Humans | Leucine - therapeutic use | Antineoplastic Agents - therapeutic use | PPAR gamma - metabolism | Cyclooxygenase 2 Inhibitors - therapeutic use | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Cyclooxygenase 2 Inhibitors - metabolism | Leucine - analogs & derivatives | Fibroblasts - metabolism | Cell Survival - drug effects | Biotinylation | Cyclooxygenase 2 Inhibitors - pharmacology | Tumor Suppressor Protein p53 - metabolism | Keratinocytes - cytology | Celecoxib - pharmacology | Celecoxib - therapeutic use | Dinoprostone - metabolism | Cell Movement - drug effects | Keratinocytes - drug effects | Keratinocytes - metabolism | Fibroblasts - drug effects | Cyclooxygenase 2 - metabolism | PPAR gamma - agonists | Cell Line, Tumor | Cell Proliferation - drug effects | Fibroblasts - cytology | Glioblastoma - drug therapy | Biological properties | COX-2 inhibitors | Energy levels | Wnt protein | p53 Protein | Brain cancer | Membrane permeability | L-leucine | Prostaglandin E2 | Cytotoxicity | Leucine | Cancer therapies | Necrosis | Anticancer properties | Nanoparticles | β-catenin | Dendrimers | Blood-brain barrier | Glioma cells | Fibroblasts | Tumorigenesis | Nonsteroidal anti-inflammatory drugs | Localization | Glutathione | Cell survival | Keratinocytes | Biotin | Inflammation | Celecoxib | Permeability | Anti-inflammatory agents | Mutants | Cell death | Medical prognosis | Antitumor activity | Peroxisome proliferator-activated receptors | Mutation | Cyclooxygenase-2 | Viability | Apoptosis | Tumors | biotinylated pamam g3 dendrimer | cox-2 inhibitor—celecoxib | pparγ agonist—fmoc-l-leucine
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2017, Volume 83, Issue 12, pp. 2718 - 2728
Journal Article
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 316 - 326
Journal Article